TEMPE, Ariz., Sept. 20, 2011 /PRNewswire/ —
Quantum Materials Corporation (www.qdotss.com
) (Pink Sheets:
QTMM) Quantum Materials Corp. and Nanoaxis, LLC announce the
formation of a technology alliance combining Quantum Materials
tetrapod quantum dot mass production technology with Nanoaxis
advanced research expertise and intellectual property in gene
therapy biomedical nanotechnology. The aim of the alliance is
to develop Tetrapod Quantum Dot based Cancer diagnostic kits and
theranostic applications including Alzheimer’s, Type 1 and Type 2
Diabetes, Breast Cancer and Major Depression.
Quantum Materials Corporation will develop specialized quantum
dots for Nanoaxis to functionalize with their proprietary
biomedical nanomaterials for a multiplexing drug delivery platform
for drug/gene therapy and diagnostic medical devices technologies.
The technology alliance allows these technologies to be developed
rapidly due to Quantum Materials’ ability to create the highest
quality quantum dots in quantities necessary to support multiple
projects with timely deliveries.
The immediate goal is to develop a QD microarray device for
detection, diagnosis and quantification of early cancers. The QD-MI
device will be designed for rapid detection and grading of various
multiple cancers using blood assays, with higher accuracy and at
less cost than current single ELISA assays. All diagnostic and
pharmaceutical products will include QMC quantum dots
functionalized by Nanoaxis biomedical IP nanotechnology.
According to a recent report published by BCC Research the total
market for nanobiotechnology products is $19.3 billion in 2010 and
is growing at a compound annual growth rate (CAGR) of 9% to reach a
forecast market size of $29.7 billion by 2015.
Stephen Squires, CEO and President of